1. Home
  2. YEXT vs PRTA Comparison

YEXT vs PRTA Comparison

Compare YEXT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yext Inc.

YEXT

Yext Inc.

HOLD

Current Price

$6.76

Market Cap

547.4M

Sector

Technology

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$9.09

Market Cap

449.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
YEXT
PRTA
Founded
2006
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
547.4M
449.7M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
YEXT
PRTA
Price
$6.76
$9.09
Analyst Decision
Buy
Buy
Analyst Count
4
9
Target Price
$7.50
$19.00
AVG Volume (30 Days)
689.5K
397.2K
Earning Date
06-02-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
131.82
N/A
EPS
0.02
0.26
Revenue
$170,201,000.00
$814,000.00
Revenue This Year
$3.95
$1,111.38
Revenue Next Year
$2.46
N/A
P/E Ratio
$325.00
$35.58
Revenue Growth
N/A
N/A
52 Week Low
$3.27
$7.73
52 Week High
$9.20
$11.80

Technical Indicators

Market Signals
Indicator
YEXT
PRTA
Relative Strength Index (RSI) 72.95 50.55
Support Level $4.77 $8.83
Resistance Level $8.04 $9.36
Average True Range (ATR) 0.21 0.37
MACD 0.04 0.04
Stochastic Oscillator 92.83 39.53

Price Performance

Historical Comparison
YEXT
PRTA

About YEXT Yext Inc.

Yext Inc provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud and sync it to approximately 200 services including Apple Maps, Bing, Cortana, Facebook, Google, Google Maps, Instagram, Siri and Yelp. Digital knowledge is the structured information that a business wants to make publicly accessible. The company also makes search intelligent by helping to provide precise, accurate and current answers to location-based queries that are conducted across the web and mobile applications and voice and artificial intelligence, or AI, engines. The company derives the majority of its revenues from subscription services. Geographically, the company generates a majority of its revenue from North America and the rest from International markets.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: